Breaking into the Billion-Dollar Healthcare Market: How AI Agents Are Pioneering New Frontiers in Medical Innovation

With 16 years of experience in the healthcare industry and investment, including extensive expertise in AI-driven healthcare, founded Probe Capital in 2017.

Since 2017, Yan Jingjing has led her team in assisting nearly 100 life sciences innovators with financing and M&A transactions, totaling over RMB 20 billion. These deals span multiple sub-sectors, including AI healthcare, innovative drugs, novel medical devices, biotechnology, healthcare services, and digital health. Notably, in the AI healthcare space, the team has executed several high-impact financing rounds for companies such as SenseTime Medical, Quanzhen Medicine, Zhiyun Health, and Jianhai Technology, driving the deep integration of artificial intelligence into scenarios like assisted diagnosis, drug R&D, and health management.

Yan Jingjing has actively promoted the digital transformation of investment industries. In 2022, she led her team to launch “Shennong No. 1,” the first AI-powered investment decision-support platform in the healthcare and life sciences sector. By leveraging neural networks, deep learning, and data analytics, the platform has built an intelligent decision-making system that encompasses modules such as global frontier technology trends, corporate innovation mapping, and clinical value assessment, thereby enhancing the efficiency and precision of primary market investments.

Mr. Yan Jingjing was responsible for establishing the Investment Department at VCBeat, serving as Investment Director, where he oversaw investor relations for the financial advisory (FA) business segment and the development of the corporate innovation ecosystem network; he also participated in post-investment management of healthcare projects at Yueyin Investment.

Bachelor’s and Master’s degrees from Peking University; recognized on the Forbes Under 30 list; named one of the 35 Outstanding Emerging Investors by the Young Investors Club; listed among the 21 Best Post-90s Investors by Lieyunwang; selected as one of the 40 Most Promising Young Direct Investment Fund Managers under 40 by Fund of Funds; honored as an Outstanding Young Investor in China’s Private Equity Industry for 2024. Focus areas include cellular intelligence, brain-computer interfaces, and AI-driven biomedical cross-disciplinary innovation. Representative investment cases: Baitong Energy (001376.SZ), E-Dianzu (02416.HK), Xintisu, Huakan Bio, Bendao Gene, Yigen Technology, Gerui Technology, and Chuanggou Bio.

Spearheaded the design and development of the “Zijing AI Hospital” system (Agent Hospital). Long dedicated to technological innovation and practical implementation in smart healthcare, covering large-model-based medical agents, intelligent analysis of medical imaging, clinical data mining driven by natural language processing, and the development of cloud-based medical collaboration systems. Received a bachelor’s degree in 2014 and a master’s degree in 2017 in Computer Science and Technology from Tsinghua University, and subsequently pursued doctoral research in Information and Communication Engineering at the University of Tokyo. Has published multiple papers in renowned international academic journals and conferences.

Holds a Ph.D. in Surgery from Peking Union Medical College and formerly served as a clinical physician in the Department of Urology at the Second Affiliated Hospital of Zhejiang University School of Medicine.

In 2013, he conducted postdoctoral research at the Johns Hopkins University School of Medicine in the United States, focusing on AI-mediated robotic surgery. His achievements were recognized as one of the Top 10 Abstracts by the American Urological Association in 2014 and are protected by international patents. He currently serves as a Distinguished Researcher at the Hangzhou Innovation Institute of Beihang University and as a Committee Member of the Artificial Intelligence Professional Committee at the First Affiliated Hospital of Zhejiang University.

Dr. Xue led the application for a key project under the National Key R&D Program’s “Modernization of Traditional Chinese Medicine” special initiative, creatively applying AIGC technology to medical practice. He pioneered in China the development of the Quanzhen Medical Large Model, a proprietary large language model with hundreds of billions of parameters that has completed algorithm registration with the Cyberspace Administration of China. By leveraging high-precision data annotation and Reinforcement Learning from Human Feedback (RLHF), he successfully transformed this model into commercial medical AI products.

Research Achievements: 3 national invention patents, 54 software copyrights, and more than 20 published papers; awarded multiple honors, including the First Prize at the National Level in the 2nd National Digital Health Innovation Application Competition and the Second Prize at the National Level in the 1st National Competition.